Edgar Filing: CLEVELAND BIOLABS INC - Form 4

CLEVELAND BIOLABS INC Form 4 February 27, 2015 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES UNITED STATES SECURITIES Section 16. Form 4 or Form 5 obligations may continue. <i>Eve</i> Instruction 1(b).									OMB Number: Expires: Estimated a burden hour response		
(Print or Type]	Responses)										
SALUCK RANDY S. Syn CL			Symbol	r Name and ELAND B			c	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) C/O CLEVELAND BIOLABS, 02/25/2015 INC., 73 HIGH STREET					X_ Director 10% Owner Officer (give title Other (specify below) below)						
DUEFALO	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
BUFFALO			Person						0		
(City)		(Zip)			Derivative	Secu	rities Acq	uired, Disposed of,	or Beneficiall	•	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactic Code (Instr. 8) Code V	(Instr. 3,	(A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$0.005 per share	02/25/2015			Р	1,891	A	\$ 3.4205	6,116	I	Held by Mortar Rock, L.P. (1)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: CLEVELAND BIOLABS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	′ (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
SALUCK RANDY S. C/O CLEVELAND BIOLABS, INC. 73 HIGH STREET BUFFALO, NY 14203	Х							
Signatures								
/s/ Leah Brownlee, Attorney-in-fact for Saluck.	S.	02/27/	2014					
**Signature of Reporting Person		Date						

Explanation of Responses:

If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Mr. Saluck is a managing member of Mortar Rock Capital Management, LLC, which manages Mortar Rock, L.P.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Deletionalia